Shufro Rose & Co. LLC raised its stake in shares of Opko Health, Inc. (NASDAQ:OPK) by 1.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 193,700 shares of the biotechnology company’s stock after buying an additional 2,000 shares during the period. Shufro Rose & Co. LLC’s holdings in Opko Health were worth $1,275,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in OPK. IFC Holdings Incorporated FL boosted its position in shares of Opko Health by 16.5% in the second quarter. IFC Holdings Incorporated FL now owns 17,864 shares of the biotechnology company’s stock worth $119,000 after buying an additional 2,525 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Opko Health by 20.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 1,095,177 shares of the biotechnology company’s stock worth $7,207,000 after buying an additional 189,438 shares in the last quarter. Blue Sky Asset Management LLC boosted its position in shares of Opko Health by 58.8% in the second quarter. Blue Sky Asset Management LLC now owns 208,110 shares of the biotechnology company’s stock worth $1,369,000 after buying an additional 77,098 shares in the last quarter. First Manhattan Co. boosted its position in shares of Opko Health by 18.3% in the second quarter. First Manhattan Co. now owns 75,000 shares of the biotechnology company’s stock worth $493,000 after buying an additional 11,600 shares in the last quarter. Finally, Essex Investment Management Co. LLC boosted its position in shares of Opko Health by 0.8% in the second quarter. Essex Investment Management Co. LLC now owns 266,949 shares of the biotechnology company’s stock worth $1,757,000 after buying an additional 2,153 shares in the last quarter. 22.94% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Opko Health, Inc. (OPK) opened at 6.16 on Tuesday. Opko Health, Inc. has a 52-week low of $5.99 and a 52-week high of $12.15. The company’s market capitalization is $3.45 billion. The company’s 50 day moving average price is $6.36 and its 200 day moving average price is $7.24.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The company had revenue of $314.20 million for the quarter, compared to analysts’ expectations of $322.64 million. During the same quarter in the prior year, the firm earned $0.02 earnings per share. Opko Health’s revenue was down 12.0% compared to the same quarter last year. On average, analysts predict that Opko Health, Inc. will post ($0.20) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Opko Health, Inc. (OPK) Position Boosted by Shufro Rose & Co. LLC” was published by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/opko-health-inc-opk-position-boosted-by-shufro-rose-co-llc/1490428.html.

Several research firms recently issued reports on OPK. Jefferies Group LLC restated a “hold” rating and set a $8.00 price target on shares of Opko Health in a research report on Monday, June 12th. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a research report on Friday, July 21st. Barrington Research raised their price target on Opko Health to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 18th. BidaskClub upgraded Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $19.50 price objective on shares of Opko Health in a research report on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $14.61.

In other news, Director John A. Paganelli acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The shares were bought at an average price of $6.17 per share, with a total value of $30,850.00. Following the completion of the purchase, the director now directly owns 350,340 shares in the company, valued at $2,161,597.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Phillip Md Et Al Frost acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, May 18th. The stock was purchased at an average cost of $6.59 per share, for a total transaction of $131,800.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $20,224,387.09. The disclosure for this purchase can be found here. In the last three months, insiders purchased 1,613,200 shares of company stock worth $10,273,059. 40.19% of the stock is owned by insiders.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health, Inc. (NASDAQ:OPK).

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.